Skip to page body Patient Care Survivorship Research Cancer Types News Giving Community Partners Clinical Trials
UCLA's Jonsson Comprehensive Cancer Center
Take the Jonsson Cancer Center Site Survey

Funding Announcements: September 2012

The following new grants were awarded to JCCC members, announced in September 2012:

.Principal Investigator: Aronson, William

Sponsor Name: Myriad Genetics, Inc.

Award Title: Effect of a Low Fat Fish Oil Diet on Prostate Cancer Progression Ccp Scoring

Principal Investigator: Chmielowski, Bartosz

Sponsor Name: Southwest oncology Group

Award Title: E1609-a Phase Iii Randomized Study of Adjuvant Ipilimumab Ati-Ctla4 Therapy Versus High-Dose Interferon a 2b for Resected High Risk Melanoma

Principal Investigator: Detels, Roger

Sponsor Name: Johns Hopkins University

Award Title: Aging and Fracture Risk Among Hiv-Infected and Hiv-Uninfected Men

Principal Investigator: Di Carlo, Dino

Sponsor Name: U.S. Navy/office of Naval Research

Award Title: Selective Cell Isolation in Microscale Vortices

Principal Investigator: Eradat, Herbert

Sponsor Name: Gilead Sciences, Inc.

Award Title: Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating The Efficacy and Safety of Gs 1101 (Cal-101) in Combination with Rituximab for Previously Treated Chronic Lymphocytic Leukemia

Principal Investigator: Ganz, Patricia

Sponsor Name: City of Hope (Beckman Research Institute)

Award Title: Low Dose Tamoxifen in Hodgkin Lymphoma Survivors for Breast Cancer Risk Reduction

Principal Investigator: Graeber, Thomas

Sponsor Name: NIH/National Cancer Institute

Award Title: Diagnosing Emergence of Kinase Inhibitor Resistance on a Microchip

Principal Investigator: Hecht, Joel

Sponsor Name: Morphotek, Inc. (Japan)

Award Title: Randomized, Double-Blind, Placebo-Controlled Study of The Efficacy & Safety of Monotherapy Morab-004 Plus Best Supportive Care in Subjects with Chemorefractory Metastatic Colorectal Cancer

Principal Investigator: Hurvitz, Sara

Sponsor Name: Novartis Pharmaceuticals (Novartis Ag (Incl Pharma,Animal Hl

Award Title: Phase III Randomized, Double Blind Placebo Controlled Study of Bkm120 with Fulvestrant, in Postmenopausal Women with Hormone Receptor-Positive Her2-Negative Locally Advanced or Metastatic Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment

Principal Investigator: Irwin, Michael

Sponsor Name: Johns Hopkins University

Award Title: Mechanisms of Sleep Distruption Hyperalgesia

Principal Investigator: Kabbinavar, Fairooz

Sponsor Name: Boehringer Ingelheim Pharmaceuticals, Inc

Award Title: Randomised, Double-Blind Phase Iii Trial Will Be Performed in Patients with Head and Neck Squamous Cell Carcinoma (Hnscc). The Objectives of The Trial Are To Compare The Efficacy and Safety of Afatinib (Bibw 2992) with Placebo As Adjuvant Therapy To Patients Who Have Received Definitive Chemo-Radiotherapy

Principal Investigator: Lai, Albert

Sponsor Name: American Brain Tumor Association

Award Title: Lalezari: Combined Analysis of O6-Methylguanine-Dna Methyltransferase (Mgmt) Protein Expression and Promoter Methylation for Optimized Prediction of Gbm

Principal Investigator: Litwin, Mark

Sponsor Name: NIH/National Library of Medicine

Award Title: Urologic Diseases in America

Principal Investigator: Martinez, Julian

Sponsor Name: March of Dimes Birth Defects Foundation

Award Title: Genetic Studies of Overgrowth Syndromes

Principal Investigator: McNitt-Gray, Michael

Sponsor Name: Mayo Clinic

Award Title: Trade-Offs in Human Observer Performance, Image Quality Metrics, and Patient Dose

Principal Investigator: Mitsuyasu, Ronald

Sponsor Name: Sangamo Biosciences, Inc.

Award Title: Phase 1, Open-Label Study To Assess The Effect of Escalating Doses of Cyclophosphamide on The Engraftment of Sb-728-T in Aviremic Hiv-Infected Subjects on Haart

Principal Investigator: Plath, Kathrin

Sponsor Name: NIH/National Institute of General Medical Sciences

Award Title: Pandya-Jones:Mechanisms of X Chromosome Silencing and Its Relation To Pluripotency

Principal Investigator: Ribas, Antoni

Sponsor Name: Genentech, Inc.

Award Title: Open-Label, Multicenter, Phase Ii Study of Continuous oral Zelboraf (Vemurafenib) in Patients with Locally-Advanced, Unresectable, Stage Iiic or Metastatic Melanoma and Activating Exon 15 Braf Mutations Other Than V600e

Principal Investigator: Ribas, Antoni

Sponsor Name: Glaxosmithkline (Merge:Glaxo Welcome/Smith Kline Beacham)

Award Title: Phase Iii, Randomized. Double-Blind Study Comparing The Combination of Hte Braf Inhibitor, Dabrafenib and The Mek Inhibitor, Trametnib To Dabrafenib

Principal Investigator: Segura, Tatiana

Sponsor Name: NIH/National Institute of Neurological Disorders & Stroke

Award Title: Vegf Ligand Presentation and Therapeutic Angiogenesis

Principal Investigator: Sharma, Sherven

Sponsor Name: U.S. Army/Medical Research Acquisition Activity

Award Title: Mesothelioma Snail-Mediated Modulation of Inflammatory Responses

Principal Investigator: Timmerman, John

Sponsor Name: Bristol-Myers Squibb Company

Award Title: Phase I Dose Escalation Study To Investigate The Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (Pd-1) Antibody (Bms-936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

 

Last updated: 11/27/2012 4:55:46 PM